'Terminator' protein halts cancer-causing cellular processes

June 03, 2020

ITHACA, N.Y. - Essential processes in mammalian cells are controlled by proteins called transcription factors. For example, the transcription factor HIF-1 is triggered by a low-oxygen situation to cause the cell to adapt to decreased oxygen.

Transcription factors operate in healthy cells, but cancer cells can co-opt transcription factors such as HIF-1 into promoting tumor growth.

New research from the lab of Hening Lin, professor of chemistry and chemical biology in the College of Arts and Sciences, finds that a protein called TiPARP acts as a terminator for several cancer-causing transcription factors, including HIF-1, which is implicated in many cancers, including breast cancer. The research demonstrates that TiPARP, therefore, is a tumor suppressor.

The paper "TiPARP Forms Nuclear Condensates to Degrade HIF-1α and Suppress Tumorigenesis," published in PNAS, establishes TiPARP as a turning-off mechanism for several important transcription factors - including HIF-1, C0-Myc and estrogen receptor - and shows how TiPARP itself is degraded during this process. The study also shows the mechanism through which TiPARP terminates these factors, another new discovery.

Co-authors are graduate student Lu Zhang; former postdoctoral fellow Ji Cao; and Longying Dong, former director of the Immunopathology Research and Development Laboratory in the College of Veterinary Medicine's Department of Biomedical Sciences.

HIF-1 is important for cancer because a lot of tumors thrive in low-oxygen conditions, said Lin, a Howard Hughes Medical Institute Investigator and corresponding author of the paper.

"For these tumors to survive, they have to rely on HIF-1," Lin said. "TiPARP is a terminator of HIF-1. Therefore, if you can activate TiPARP, then you can suppress [tumor growth]."

Lin and co-authors are also excited by the discovery of the mechanism through which TiPARP brings about the termination of HIF-1 and other transcription factors. This mechanism, called "liquid-liquid phase separation" or "phase condensation," is a topic of great interest in biology.

Imagine drops of vinegar in oil: The vinegar forms distinct droplets suspended in the more viscous oil.

Similarly, when TiPARP is activated in a cell nucleus, it forms the so-called "phase separation" that recruits HIF-1-alpha and HUWE1 (an ubiquitin protein ligase) in the cell nucleus. This starts a process through which HIF-1-alpha and TiPARP both deactivate and degrade.

Through phase separation, TiPARP terminates not just HIF-1 but several different transcription factors implicated in different types of cancer, Lin said.

In fact, TiPARP may already be at work in Tamoxifen, a widely used breast cancer drug. Lin thinks Tamoxifen, which successfully treats estrogen receptor-positive breast cancers, works because TiPARP is actively terminating estrogen receptor, HIF-1 and c-Myc in tumors.

"When Tamoxifen and similar compounds were developed as estrogen receptor agonists or antagonists, we did not even know what compounds would be better," he said. "Now we think the idea will be, what compound can activate TiPARP better?"
This research received support from the Howard Hughes Medical Institute, Cornell's College of Arts and Sciences, and the National Institutes of Health.

Cornell University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.